Janux Therapeutics (JANX) Competitors

Janux Therapeutics (NASDAQ:JANX) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Does the media favor JANX or GRFS?

In the previous week, Janux Therapeutics had 4 more articles in the media than Grifols. MarketBeat recorded 8 mentions for Janux Therapeutics and 4 mentions for Grifols. Janux Therapeutics' average media sentiment score of 1.09 beat Grifols' score of 1.04 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is JANX or GRFS more profitable?

Grifols has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Grifols' return on equity of 0.00% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	-463.91%	-10.47%	-9.86%
Grifols	N/A	N/A	N/A

Do analysts rate JANX or GRFS?

Janux Therapeutics currently has a consensus target price of $95.25, indicating a potential upside of 263.00%. Given Janux Therapeutics' higher possible upside, analysts plainly believe Janux Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.09
Grifols	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Do institutionals and insiders believe in JANX or GRFS?

75.4% of Janux Therapeutics shares are owned by institutional investors. 8.1% of Janux Therapeutics shares are owned by insiders. Comparatively, 0.2% of Grifols shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has higher valuation & earnings, JANX or GRFS?

Grifols has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$9.34M	166.32	-$58.29M	-$1.36	-19.29
Grifols	$7.21B	0.86	$64.20M	$1.17	7.71

Which has more volatility and risk, JANX or GRFS?

Janux Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Does the MarketBeat Community favor JANX or GRFS?

Grifols received 308 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 70.97% of users gave Janux Therapeutics an outperform vote while only 56.23% of users gave Grifols an outperform vote.

Company	Underperform	Outperform
Janux Therapeutics	Outperform Votes 44 70.97%	Underperform Votes 18 29.03%
Grifols	Outperform Votes 352 56.23%	Underperform Votes 274 43.77%

Summary

Janux Therapeutics beats Grifols on 10 of the 19 factors compared between the two stocks.